Adagene Inc

NASDAQ ADAG

Data sourced from

and

Download Data

Adagene Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the quarter ending December 31, 2023: -6.09%

Adagene Inc Net Working Capital to Total Assets Ratio 3 year CAGR is -6.09% for the quarter ending December 31, 2023. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Adagene Inc Net Working Capital to Total Assets Ratio for the quarter ending December 31, 2022 was 0.62, a -24.95% change year over year.
Adagene Inc Net Working Capital to Total Assets Ratio for the quarter ending December 31, 2021 was 0.82, a 10.28% change year over year.
Adagene Inc Net Working Capital to Total Assets Ratio for the quarter ending December 31, 2020 was 0.75, a -18.23% change year over year.
Adagene Inc Net Working Capital to Total Assets Ratio for the quarter ending December 31, 2019 was 0.91.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends